Overview

CAFE Comparison of Atypicals in First Episode of Psychosis

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
University of North Carolina
Treatments:
Olanzapine
Risperidone